Baodong Sun

发表

Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease

S. Borneman, P. Kishnani, H. Yi, 2017, Journal of Molecular Medicine.

Gene therapy for glycogen storage diseases.

D. Koeberl, P. Kishnani, Baodong Sun, 2019, Human molecular genetics.

Transcriptomic and Proteomic Analysis of Clear Cell Foci (CCF) in the Human Non-Cirrhotic Liver Identifies Several Differentially Expressed Genes and Proteins with Functions in Cancer Cell Biology and Glycogen Metabolism

D. Calvisi, T. Kietzmann, S. Ribback, 2020, Molecules.

D. Calvisi, T. Kietzmann, S. Ribback, 2020, bioRxiv.

Characterization of liver GSD IX γ2 pathophysiology in a novel Phkg2-/- mouse model.

Jeong-A Lim, D. Bali, A. Asokan, 2021, Molecular genetics and metabolism.

Visible/near-IR-light-driven TNFePc/BiOCl organic-inorganic heterostructures with enhanced photocatalytic activity.

Xitian Zhang, Lu Li, Mingyi Zhang, 2016, Dalton transactions.

Therapeutic Benefit of Autophagy Modulation in Pompe Disease.

R. Puertollano, N. Raben, Jeong-A Lim, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation.

P. Kishnani, L. Case, S. Austin, 2017, Molecular genetics and metabolism.

Adjunctive β2‐agonists reverse neuromuscular involvement in murine Pompe disease

M. Tarnopolsky, Songtao Li, D. Bali, 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.

Songtao Li, D. Bali, D. Koeberl, 2011, Molecular genetics and metabolism.

Preclinical Development of New Therapy for Glycogen Storage Diseases.

D. Koeberl, Baodong Sun, E. D. Brooks, 2015, Current gene therapy.

Activation of glycolysis and apoptosis in glycogen storage disease type Ia.

Songtao Li, D. Koeberl, A. Diehl, 2009, Molecular Genetics and Metabolism.

New Insights into Gastrointestinal Involvement in Late-Onset Pompe Disease: Lessons Learned from Bench and Bedside

Jeong-A Lim, K. Zimmerman, P. Kishnani, 2021, Journal of clinical medicine.

Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.

M. Kulis, Songtao Li, D. Koeberl, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.

R. Auten, Songtao Li, Zhen Yan, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.

R. Rodriguiz, A. Kemper, D. Koeberl, 2012, Human gene therapy.

Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector.

D. Koeberl, A. Amalfitano, Baodong Sun, 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.

D. Koeberl, D. K. Benjamin, Baodong Sun, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.

D. Koeberl, Baodong Sun, Haoyue Zhang, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.

D. Koeberl, P. Kishnani, Baodong Sun, 2007, American journal of human genetics.

Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.

D. Koeberl, A. Amalfitano, Baodong Sun, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.

D. Koeberl, A. Amalfitano, T. Clay, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Natural Progression of Canine Glycogen Storage Disease Type IIIa.

J. Fyfe, B. Thurberg, P. Kishnani, 2016, Comparative medicine.

AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.

Yuan-Tsong Chen, Songtao Li, D. Koeberl, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Antibody formation and mannose‐6‐phosphate receptor expression impact the efficacy of muscle‐specific transgene expression in murine Pompe disease

A. Kemper, Songtao Li, D. Koeberl, 2010, The journal of gene medicine.

Hydrostatic Isolated Limb Perfusion with Adeno-associated Virus Vectors Enhances Correction of Skeletal Muscle in Pompe Disease

Songtao Li, D. Koeberl, Baodong Sun, 2010, Gene Therapy.

Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease

H. Waldmann, A. Rosenberg, A. D. de Fougerolles, 2014, Molecular genetics and metabolism reports.

Characterization of a canine model of glycogen storage disease type IIIa

J. Fyfe, D. Koeberl, B. Thurberg, 2012, Disease Models & Mechanisms.

Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high‐level vector‐mediated transgene expression

Songtao Li, D. Koeberl, Baodong Sun, 2009, The journal of gene medicine.

A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease

Fengqin Gao, T. Kishimoto, P. Kishnani, 2017, Molecular genetics and metabolism reports.

Starch Binding Domain-containing Protein 1 Plays a Dominant Role in Glycogen Transport to Lysosomes in Liver*

P. Kishnani, H. Yi, Tao Sun, 2016, The Journal of Biological Chemistry.

A Modified Enzymatic Method for Measurement of Glycogen Content in Glycogen Storage Disease Type IV.

P. Kishnani, H. Yi, Chunyu Yang, 2016, JIMD reports.

Hepatic Manifestations in Glycogen Storage Disease Type III

P. Kishnani, S. Austin, Baodong Sun, 2018, Current Pathobiology Reports.

Adjunctive (cid:1) 2-agonists reverse neuromuscular involvement in murine Pompe disease

M. Tarnopolsky, Songtao Li, D. Bali, 2012 .

Correction of glycogen storage disease type III with rapamycin in a canine model

J. Fyfe, B. Thurberg, P. Kishnani, 2014, Journal of Molecular Medicine.

IL-37 is associated with osteoarthritis disease activity and suppresses proinflammatory cytokines production in synovial cells

Dongzhou Liu, X. Hong, Lingyun Li, 2017, Scientific Reports.

Comparative proteome analysis of peripheral blood mononuclear cells in systemic lupus erythematosus with iTRAQ quantitative proteomics

Z. Tu, Baodong Sun, S. Qi, 2012, Rheumatology International.

Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type Ia.

D. Little, D. Koeberl, M. Freemark, 2013, Molecular genetics and metabolism.

Elevated interleukin-37 associated with tophus and pro-inflammatory mediators in Chinese gout patients.

Shuhui Meng, Dongzhou Liu, X. Hong, 2021, Cytokine.

Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy.

B. Thurberg, P. Kishnani, H. Yi, 2017, Human gene therapy.

Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV

Fengqin Gao, P. Kishnani, H. Yi, 2016, Molecular genetics and metabolism reports.

Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis

Baodong Sun, Yu-Lan Chen, Cuilian Liu, 2022, Frontiers in Immunology.

Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease

Fengqin Gao, N. Raben, Jeong-A Lim, 2019, Molecular therapy. Methods & clinical development.

A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme

Fengqin Gao, Jeong-A Lim, P. Kishnani, 2020, Molecular therapy. Methods & clinical development.

Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice

Jeong-A Lim, P. Kishnani, Baodong Sun, 2022, JCI insight.

Correction of glycogen storage disease type III with rapamycin in a canine model

J. Fyfe, B. Thurberg, P. Kishnani, 2014, Journal of Molecular Medicine.

867. Correction of Glycogen Storage Disease Type II by Intramuscular Administration of an Adeno-Associated Virus 6 (AAV2/6) Vector Containing a Muscle-Specific Promoter

D. Koeberl, Baodong Sun, Haoyue Zhang, 2004 .

Stbd1 is highly elevated in skeletal muscle of Pompe disease mice but suppression of its expression does not affect lysosomal glycogen accumulation.

P. Kishnani, H. Yi, Baodong Sun, 2013, Molecular genetics and metabolism.

An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Jeong-A Lim, P. Kishnani, Baodong Sun, 2019, Annals of translational medicine.

Successful AAV8 readministration: Suppression of capsid‐specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease

W. Jeck, Jeong-A Lim, T. Tedder, 2023, The journal of gene medicine.

Gene therapy for glycogen storage diseases

Jeong-A Lim, D. Koeberl, P. Kishnani, 2023, Journal of inherited metabolic disease.

Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.

W. Kraus, Yuan-Tsong Chen, D. Bali, 2013, Molecular genetics and metabolism.

Therapeutic Benefit of Autophagy Modulation in Pompe Disease.

R. Puertollano, N. Raben, Jeong-A Lim, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.

R. Rodriguiz, A. Kemper, D. Koeberl, 2012, Human gene therapy.

Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease

S. Borneman, P. Kishnani, S. Austin, 2017, Journal of Molecular Medicine.

Starch Binding Domain-containing Protein 1 Plays a Dominant Role in Glycogen Transport to Lysosomes in Liver*

P. Kishnani, Tao Sun, Chunyu Yang, 2016, The Journal of Biological Chemistry.

Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia

D. Millington, D. Koeberl, Baodong Sun, 2006, Gene Therapy.

Sinus bradycardia induced by thalidomide in rheumatic disease : two case reports

X. Hong, Baodong Sun, Dongyan Liu, 2018 .

Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high‐level vector‐mediated transgene expression

Songtao Li, D. Koeberl, Baodong Sun, 2009, The journal of gene medicine.